Risk Management for Aseptic Processing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Risk Management for Aseptic Processing
The author discusses the risks involved with aseptic processing, methods and tools used to identify and control risk, and regulatory guidelines relevant to the risk-management process.

Pharmaceutical Technology


Quality risk management is an essential tool for qualification of aseptic processes. It is not just a tool for CGMP compliance; it offers real benefits to the validation process by identifying risks and ensuring that critical risks are controlled. By focusing managing risks to the patient, pharmaceutical manufacturers can ensure that the right resources are applied at the right place at the right time—improving patient safety while eliminating unnecessary validation efforts.

Ed White is a QA validation specialist at Baxter Healthcare Corporation, 1700 Rancho Conejo Blvd., Thousand Oaks, CA, 805.375.6779,
. This article was first published in The Journal of Validation Technology, Vol. 15, Num. 2, Spring 2009.


1. FDA, Pharmaceutical CGMPs for the 21st Century—A Risk Based Appoach (Rockville, MD, Aug. 2002).

2. ICH Q9 Quality Risk Management, Nov. 9, 2005.

3. PDA, Technical Report No. 44, Quality Risk Management for Aseptic Processes, 2008 Supplement, Volume 62, No. S-1.

4. Oliver, James, J. of Valid. Technol., 14, (5), Autumn 2008.

5. WHO, Annex 7: Application of Hazard Analysis and Critical Control Point (HACCP) Methodology to Pharmaceuticals, WHO Expert Committee on Specifications for Pharmaceutical Preparations, Thirty-Seventh Report, Geneva, Switzerland, 2003.

6. FDA, Draft Guidance for Industry—Process Validation: General Principles and Practices (Rockville, MD, Nov. 2008).

7. European Commission, Enterprise Directorate—General, Working Party on Control of Medicines and Inspections, Final Version of Annex 15 to the EU Guide to Good Manufacturing Practice: Qualification and Validation, Sept. 2001.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here